AJANTPHARM

Ajanta Pharma today (May 6 2026) reported a strong Q4 FY26

Ajanta Pharma today (May 6 2026) reported a strong Q4 FY26 performance with revenue up 21% YoY to ₹1,422 crore and net profit rising 18% to ₹267 crore. Shares gained 5% to ₹3,042 on the NSE after robust growth in its US generics segment (+56% YoY) Segment Performance US Generics: Revenue ₹505 crore (+56% YoY) — key growth driver. FY26 total ₹1,557 crore (+49% YoY). Multiple ANDA filings await US FDA approval. India Branded Generics: Revenue ₹404 crore (+9% YoY) — steady domestic demand. Africa Branded Generics: Revenue ₹182 crore (+37% YoY) — strong regional momentum. Asia Branded Generics: Revenue ₹274 crore (−10% YoY) — temporary slowdown offset by other regions. Full‑Year FY26 Summary Revenue: ₹5,453 crore (+17% YoY) PAT: ₹1,056 crore (+15% YoY) EBITDA: ₹1,395 crore (+11% YoY) with 26% margin R&D Spend: ≈ 5% of revenue to strengthen pipeline Forex Impact: ₹42 crore mark‑to‑market loss in Q4